Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
40 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
- Males and Females aged 40-80 with a confirmed diagnosis of sporadic Inclusion Body Myositis
Unable to walk at least 3 meters without assistance from another person
Use of oral beta agonists, oral corticosteroids, androgens or androgen inhibitors, or intravenous gamma globulin in the last 6 months
patients with a history or presence of renal impairment and/or liver disease
Other protocol-defined inclusion/exclusion criteria may apply